Jiangsu Nhwa Pharmaceutical: Revenue up 3.75%, net profit down 7.54%, strong R&D and cash flow, dividend proposed

About this update from Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A

Revenue grew 3.75% to ¥5.91 billion, but net profit fell 7.54% to ¥1.06 billion due to higher R&D and operating costs. The company maintained strong cash flow, expanded its CNS drug pipeline, and proposed a ¥4.00 per 10 shares dividend.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Jiangsu Nhwa Pharmaceutical Co., Ltd. Class A